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Abstract
The tumor suppressor p53 is a transcription factor whose function is critical for maintaining
genomic stability in mammalian cells. In response to DNA damage, p53 initiates a signaling
cascade that results in cell cycle arrest, DNA repair or, if the damage is severe, programmed cell
death. In addition, p53 interacts with repair proteins involved in homologous recombination.
Mitotic homologous recombination (HR) plays an essential role in the repair of double-strand
breaks (DSBs) and broken replication forks. Loss of function of either p53 or HR leads to an
increased risk of cancer. Given the importance of both p53 and HR in maintaining genomic
integrity, we analyzed the effect of p53 on HR in vivo using Fluorescent Yellow Direct Repeat
(FYDR) mice as well as with the sister chromatid exchange (SCE) assay. FYDR mice carry a
direct repeat substrate in which an HR event can yield a fluorescent phenotype. Here, we show
that p53 status does not significantly affect spontaneous HR in adult pancreatic cells in vivo or in
primary fibroblasts in vitro when assessed using the FYDR substrate and SCEs. In addition,
primary fibroblasts from p53 null mice do not show increased susceptibility to DNA damage-
induced HR when challenged with mitomycin C. Taken together, the FYDR direct repeat assay
and SCE analysis indicate that, for some tissues and cell types, p53 status does not greatly impact
HR.
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1. Introduction
The p53 tumor suppressor gene is a transcription factor that plays an essential role in
maintaining genomic stability. Indeed, greater than half of all tumors have lost p53 function
[1–5]. Inherited mutations in p53 cause Li-Fraumeni syndrome, a genetic disorder
characterized by an early incidence of cancer [6, 7], and p53 null mice develop tumors at an
accelerated rate [8]. Together, these data indicate that p53 is a key inhibitor of tumor
formation, and loss of p53 function provides cells with critical selective advantages for
tumor formation.
© 2011 Elsevier B.V. All rights reserved.
*Corresponding Author: 77 Massachusetts Avenue, 16-743, Cambridge, MA 02139, Tel: 617-258-0260, Fax: 617-258-5424,
bevin@mit.edu.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
DNA Repair (Amst). Author manuscript; available in PMC 2012 December 10.
Published in final edited form as:
DNA Repair (Amst). 2011 December 10; 10(12): 1294–1299. doi:10.1016/j.dnarep.2011.09.009.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
p53 mediates cell cycle arrest and/or apoptosis in response to DNA damage. Cells are
constantly exposed to endogenous and exogenous agents that can damage DNA [9]. Of the
many lesions that form, DNA double-strand breaks (DSBs) are among the most cytotoxic
and mutagenic, and mitotic homologous recombination (HR) provides a critical pathway for
their repair [9]. In addition, HR provides the only pathway for accurate repair of broken
replication forks [10]. Thus, HR is a critical for preventing tumor-promoting sequence
rearrangements.
As with inherited mutations in p53, germline mutations in genes that modulate HR are also
associated with an increased risk of cancer [11–15]. Exchanges between misaligned
sequences can lead to tumorigenic rearrangements and loss of heterozygosity. While too
much HR can be problematic [15–17], too little HR can also lead to genomic instability. In
the absence of HR, misrepair can lead to large-scale sequence rearrangements. Indeed,
germline mutations that suppress HR (i.e., BRCA1 [18], BRCA2 [19], FANCC [20])
increase the risk of cancer [15, 21, 22]. Thus, maintaining the accuracy and the rate of HR is
critical for preventing tumor formation.
Given the importance of both p53 and HR in maintaining genomic stability, a number of
studies have focused on the effect of p53 status on HR. While some in vitro studies suggest
that p53 suppresses HR [23–29], many other studies do not show any effect of p53 on HR
[30–35]. Although the number of studies performed in vivo is limited, several investigators
have nevertheless studied HR in p53 null mice in vivo. These studies show either no effect
or a slight suppressive effect of p53 on HR [11, 36, 37]. Taken together, there is limited
information about the in vivo effect of p53 on HR in adult tissues.
Here, we investigate the impact of p53 on HR. We used the Fluorescent Yellow Direct
Repeat (FYDR) mice, in which an HR event at an integrated transgene yields a fluorescent
signal [38]. Analysis of pancreata from Fydry/y;p53+/+ and Fydry/y;p53−/− mice shows that
the frequency of recombinant cells is not affected by p53 in vivo. Since HR plays a critical
role in the repair of broken replication forks, we further analyzed the effect of p53 on HR in
rapidly dividing primary fibroblasts. However, p53 had no effect on the rate of spontaneous
or damage-induced HR in vitro. Taken together, loss of p53 does not significantly impact
SCEs or HR at the FYDR substrate in vitro or in vivo. These data call attention to the
possibility that the impact of p53 on HR is cell type-dependent.
2. Materials and Methods
2.1 Animals
FYDR [38] and p53 mice [39] were described previously. 9 week old Fydry/y;p53+/+ and
Fydry/y;p53−/− littermates were compared in a sex-matched fashion.
2.2 Flow Cytometry
Pancreatic cells were disaggregated as described previously [40]. Disaggregated pancreatic
cells were pelleted and resuspended in 350 µl OptiMEM (Invitrogen), filtered (35 µm), and
analyzed with a Becton Dickinson FACScan flow cytometer (excitation 488 nm, argon
laser). On average, ~1 million cells were analyzed per sample.
2.3 Imaging
Pancreata were imaged as described previously [40]. Briefly, whole pancreata were
compressed to 0.5 mm and imaged using a fixed aperature time (1× objective). Filters
included: visible light; UV-2E/C (Ex:330–380 nm, Em:420 nm); Red (Ex:540/25 nm, Em:
605/55 nm); and EYFP (Ex:460–500 nm, Em:510–560 nm). Foci were counted in a blinded
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fashion. Pancreata surface area was determined using Scion Image Beta 4.02 Win (Scion
Corporation).
2.4 Isolation of Ear Fibroblasts
Ears were isolated, minced, and incubated at 37°C in 4 mg/ml collagenase/dispase (Roche
Applied Sciences). After 1 hour, two volumes of fibroblast medium were added [Dulbecco's
Modified Eagle's Medium, 15% FBS, 100 units/ml penicillin, 100 µg/ml streptomycin, 0.3
mg/ml L-glutamine, 0.1mM Non-Essential Amino Acids, 5 µg/ml amphotericin B (Sigma)].
After 24 hours at 37°C and 5% CO2, cells were triturated, filtered (70-µm mesh; Falcon),
and seeded into dishes.
2.5 SCE analysis
Primary ear fibroblasts from age and sex-matched Fydry/y;p53+/+ and Fydry/y;p53−/−
littermates were seeded at 2 × 105 cells per well. After 24 hours, cells were cultured in10
µM BrdU in McCoys media. After ~22 hr, cells were incubated for ~2 hr in 0.1 µg/ml
Colcemid, and SCEs were analyzed as previously described [41]. SCEs from 25–30
metaphase spreads per genotype were counted in a blinded fashion. Analysis was performed
on passage-matched samples (<5 passages).
2.6 Calculation of Rate in Primary Fibroblasts
Primary ear fibroblasts were isolated from sex-matched Fydry/y;p53+/+ and Fydry/y;p53−/−
littermates and rate experiments were performed in parallel. For rate experiments, ~104 cells
were seeded into each of 24 independent cultures. Cultures were expanded to ~106 cells
prior to flow cytometry. Freshly isolated fibroblasts were used for each experiment (passage
2). The MSS Maximum Likelihood Method was used to calculate the rate of recombination,
as described [42]. Rate experiments were repeated with fibroblasts from seven different
pairs of mice.
2.7 Quantification of spontaneous and DNA damage-induced recombinant cell frequency
Primary ear fibroblasts from sex-matched Fydry/y;p53+/+ and Fydry/y;p53−/− littermates
were seeded at 5 × 105 cells per 100 mm dish. After 24 hours, quadruplicate samples were
cultured in Dulbecco’s Modified Eagle’s Medium or exposed to medium supplemented with
0.5 µg/ml mitomycin-C (CAS No 50-07-7) for 1 hour. After 72 hours, samples were
analyzed by flow cytometry. Population growth was determined using a Coulter counter.
Experiments were repeated with fibroblasts from three different cohorts.
3. Results
3.1 Effect of p53 status on spontaneous homologous recombination in pancreatic cells
To study HR in vivo, we previously developed FYDR mice that carry a direct repeat
recombination substrate containing two differently mutated copies of the coding sequence
for enhanced yellow fluorescent protein (EYFP). An HR event can restore full length EYFP
coding sequence (Fig. 1) [38]. One method for measuring the in vivo frequency of
fluorescent recombinant cells is to analyze disaggregated tissue by flow cytometry [40]. To
determine the effect of p53 status on HR in vivo, we analyzed recombinant cells in pancreata
of 9 week-old Fydry/y;p53+/+ and Fydry/y;p53−/− mice. The median frequency of
recombinant pancreatic cells is not significantly different between the two cohorts (Fig. 2A).
Analysis of FYDR pancreata by flow cytometry requires tissue disaggregation; thus, the
contribution of clonal expansion versus independent HR events on recombinant cell
frequency cannot be determined [40, 43, 44]. We previously developed in situ imaging
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techniques that enable the direct detection of fluorescent recombinant foci (recombination
events; see Fig. 1 [40]). For the Fydry/y;p53+/+ and Fydry/y;p53−/− mice, the median number
of recombinant foci is not significantly different between the two cohorts (Fig. 2B).
Additionally, because the sizes of pancreata vary among mice within each cohort (data not
shown), we analyzed the number of foci per unit surface area, and again found that the
frequencies of recombinant foci per cm2 are not significantly different (Fig. 2C). Although
there is significant variation among individual animals, previous studies show that relatively
subtle differences in the median value can nevertheless be detected. For example, a ~3 fold
difference in recombination frequency was observed using fewer mice than in this study
[40]. Thus, these data indicate that p53 status does not significantly impact the susceptibility
of adult pancreatic cells to HR in vivo.
3.2 Effect of p53 Status on HR in Primary Fibroblasts in vitro
HR activity is most active during S phase and late S/G2 [45], however, in the pancreas, the
vast majority of cells are not in S phase [46]. To explore the effect of p53 status on HR in
rapidly dividing cells, we created primary ear fibroblast cultures from Fydry/y;p53+/+ and
Fydry/y;p53−/− mice, and analyzed genome-wide HR events using the sister chromatid
exchange (SCE) assay [47]. There is not a significant difference in the frequency of
spontaneous SCEs in Fydry/y;p53+/+ and Fydry/y;p53−/− primary ear fibroblasts (Fig 3A).
Primary fibroblasts were also analyzed via flow cytometry. No difference was observed in
the frequency of fluorescent recombinant cells among p53+/+ and p53−/− cultures (Fig. 3B).
As another independent approach to explore p53’s potential effects on HR, we measured the
rate of HR per cell division. For each experiment, 24 independent cultures were allowed to
expand prior to analysis and the recombination rate was calculated using the MSS Maximum
Likelihood Method [42]. We found that the rate of homologous recombination is not
significantly different between Fydry/y;p53−/− and Fydry/y;p53+/+ fibroblasts (Fig. 3C).
Thus, taken together, these studies of HR using the FYDR system and the traditional SCE
assay show that p53 status does not affect the spontaneous frequency or rate of HR in
primary fibroblasts in vitro.
To determine if p53 impacts HR induced by an exogenous agent, we treated primary
fibroblasts with a potent recombinogen, mitomycin-C (MMC), and assayed both cell
proliferation and HR frequency. Consistent with being resistant to cell cycle arrest and to
apoptosis, untreated p53−/− cells had a proliferative advantage (compare black bars in Fig.
3D) [48]. When challenged with MMC, Fydry/y;p53+/+ and Fydry/y;p53−/− fibroblasts both
show significant growth inhibition (see black versus gray bars in Fig. 3D). We next queried
MMC-induced HR. For both Fydry/y;p53+/+ and Fydry/y;p53−/− fibroblasts, there is a
statistically significant increase in the frequency of recombinant cells for MMC-treated
cultures (compare black and gray bars in Fig. 3E). However, p53−/− cells did not show an
increase in susceptibility to MMC-induced HR events.
4. Discussion
As guardian of the genome, p53 function is important for maintaining genomic integrity and
loss of p53 results in an early onset and increased frequency of many types of cancers [6, 7,
39]. In response to DNA damage, p53 promotes the repair of DNA damage by inducing cell
cycle arrest and activating DNA repair proteins. However, in the presence of extensive DNA
damage, p53 signals for the elimination of damaged cells through apoptosis [49]. Due to
p53’s critical role in suppressing cancer, we set out to understand the mechanisms through
which loss of p53 promotes genomic instability.
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A number of studies have shown the direct involvement of p53 in HR. Specifically, p53 may
act at stalled replication forks to prevent breakdown [50, 51]. Additionally, p53 can directly
interact with and inhibit the function of HR proteins, including RPA [52], Rad51 [53, 54],
BLM and WRN [55–57]. Finally, p53 has been shown to bind to Holliday Junctions [57–
59]. Thus, a clear interaction between p53 and HR exists and some of its activities suggest
that p53 would suppress HR. However, using FYDR mice we found that p53 status has no
effect on HR in vivo in pancreatic cells or in vitro in primary fibroblasts, suggesting that the
role of p53 in modulating spontaneous HR in vivo is minimal in at least some cell types.
Thus, p53's tumor suppressor function may be more reliant on suppression of other forms of
genomic instability and/or on other attributes of p53, rather than on its potential to suppress
HR.
Using two different mouse models, previous studies examining the effect of p53 status on
HR in vivo show different results. In pink-eyed unstable (pun) mice, HR at a direct repeat
during embryonic development can give rise to a dark spot on the fur or on the retinal
epithelium [60, 61]. Using the fur spot assay, p53 had no effect on HR in vivo [36].
However, another study using the more sensitive pun eye-spot assay showed that loss of p53
increased HR events, specifically during early embryonic development [11]. Because clonal
expansion of recombined cells is required to detect spots on fur and retinal epithelium, pun
mice can only be used to detect recombination events that occur during embryogenesis. In
contrast, FYDR mice can be used to detect recombination events that occur in adult tissues
in vivo. Therefore, p53 may be less important in suppressing HR in adult versus embryonic
tissues.
In addition to possible differences among stages of development, the effect of p53 on HR
may be cell type specific. Indeed, studies using the adenine phosphoribosyltransferase (Aprt)
mouse model to detect recombination events in vivo showed that while fibroblasts derived
from p53−/− mice had ~2 fold increase in spontaneous mutation events due to mitotic
recombination; there was no difference in p53−/− compared to p53+/+ T lymphocytes [37,
62]. Together, these data show that p53 may have different effects on HR in different cell
types.
When considering the in vivo data, it is important to consider the limitations of the assay
used here. It is noteworthy that there is a significant amount of variability from mouse to
mouse. Some of this variation is due to stochastic factors, such as the timing of the
recombination event, which can influence the total number of recombinant cells as a
consequence of clonal expansion. Despite this variance, in older animals and in animals
exposed to DNA damaging agents, a change in the median value has been observed,
indicating that this approach can be used effectively to detect endogenous and exogenous
factors that impact homologous recombination [40, 43]. Given that we did not detect an
impact of p53 status on HR, even when analyzed with multiple approaches, we conclude
that p53 has at most a subtle impact on HR in adult animals, at least in some tissues.
The effect of p53 function on HR has also been examined in vitro in multiple cell types. In
studies using systems that detect HR events at specific loci (e.g., Tk, EGFP, SV40), the
majority suggest that p53 suppresses HR in vitro [23–26, 28, 29, 63–65]. In contrast,
virtually all studies analyzing the effect of p53 on HR by examining SCEs show no effect of
p53 function on HR [32, 34, 35, 66–70]. Additional SCE studies reveal that p53 does not
significantly impact damage-induced HR when cells are exposed to a variety of agents
(mitomycin-C, nitric oxide, low dose radiation and low dose UV) [66–70]. Thus, the
observation here that p53 does not impact SCEs is consistent with previous studies.
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It is clear that HR is dependent on multiple factors, including stage of development, cell
type, and detection method. Interestingly, Slebos and Taylor found that p53 status
influenced one type of HR reporter system, but not another [31]. Furthermore, p53 appears
to act differently in different types of recombination events, depending on the amount of
homology between the sequences [23, 28, 71, 72]. Finally, different types of mutations in
the p53 gene (e.g., null versus a point mutation) have different effects on HR [23, 29, 64,
73]. Here, we have shown that in cells and tissues of mice lacking p53, there is not a
significant effect on recombination in vivo or in vitro when assessed at a direct repeat or via
SCEs. Taken together, previous studies and the results presented here suggest a rather
complex relationship between p53 and HR, which is consistent with p53’s highly pleiotropic
roles in cell behavior. Finally, this study, in combination with the results from several others
[34–37, 72], emphasizes the extent to which HR is independent of p53 in many normal cells
and tissues.
Highlights
► p53 does not impact homologous recombination at a direct repeat in mouse pancreata
► p53 null fibroblasts show normal levels of homologous recombination and sister
chromatid exchanges. ► p53 does not appear to be a major factor in modulating HR in
some cell types in vivo.
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Fig 1.
FYDR system and analysis of the effect of p53 on HR in vivo. (A) Arrangement of the
FYDR recombination substrate: large arrows indicate expression cassettes; yellow boxes
show coding sequences; black boxes show positions of deleted sequences (deletion sizes not
to scale). (B) Compiled image for representative FYDR pancreata. Cell nuclei were stained
with Hoechst and imaged using a UV-2E/C filter (435–485 nm). Image was collected at 1×
using an EYFP filter (510–560 nm). Insert is an individual fluorescent cell.
Wiktor-Brown et al. Page 11
DNA Repair (Amst). Author manuscript; available in PMC 2012 December 10.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig 2.
Effects of p53 status on Homologous recombination in vivo. (A) Spontaneous frequency of
recombinant pancreatic cells per million as determined by flow cytometry for Fydry/y;p53+/+
(n=49) and Fydry/y;p53−/− (n=47) mice. Points on the x-axis indicate individual mice with
zero recombinant cells. (B) Spontaneous recombinant foci per pancreas detected by in situ
image analysis for Fydry/y;p53+/+ (n=48) and Fydry/y;p53−/− (n=47) mice. (C) Spontaneous
recombinant foci per cm2 detected by in situ image analysis for Fydry/y;p53+/+ (n=47) and
Fydry/y;p53−/− (n=47) mice. Medians are indicated by black bars.
Wiktor-Brown et al. Page 12
DNA Repair (Amst). Author manuscript; available in PMC 2012 December 10.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig 3.
Effects of p53 status on HR in vitro (A) Effect of p53 status on SCEs. Frequency of SCE
events in primary mouse ear fibroblasts (p=0.35, 2-tailed Student’s t-test). (B) Frequency of
recombinant fluorescent primary fibroblasts. Three independent experiments were
performed in quadruplicate, and the average of the three experiments is shown (p=0.32, 2-
tailed Student’s t-test). (C) Rate of HR in primary fibroblasts as determined by the MSS
Maximum Likelihood Method [42] (p=0.16, 2-tailed Student’s t-test). Each bar indicates the
average of 7 independent experiments. (D) Cell density (black bars) and MMC-treated (gray
bars) primary fibroblasts. Each bar indicates the average of three independent experiments,
each performed in quadruplicate. * p<0.0001, 2-tailed Student’s t-test. (E) Frequency of
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recombinant cells for mock- (black bars) and MMC-treated (gray bars) fibroblasts. Each bar
indicates the average of three independent experiments, each performed in quadruplicate.
Note that data for the mocktreated samples is also shown in part B. * p<0.0005, 2-tailed
Student’s t-test. Error bars indicate 1 SD.
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